Paper34646385
Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.
Morand du Puch CB and 5 others. Theranostics, 2021. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept. Papers, record 34646385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34646385
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Precision Medicine | Major topic |
| Biological Assay | |
| Biomarkers, Pharmacological | |
| Biomarkers, Tumor | |
| Humans | |
| Medical Oncology | |
| Pathology, Molecular |
Source PubMed
References186
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24649243 | Clinical predictive value of in vitro anticancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stage II-III colorectal cancer. | Mol Clin Oncol | 2013 | https://conductscience.org/library/papers/24649243 | PubMed |
| 2 | 23959905 | Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo. | Int J Cancer | 2014 | https://conductscience.org/library/papers/23959905 | PubMed |
| 3 | 32348737 | Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation. | Trends Cancer | 2020 | https://conductscience.org/library/papers/32348737 | PubMed |
| 4 | 22461093 | Pharmacogenetics: implementing personalized medicine. | Clin Cases Miner Bone Metab | 2009 | https://conductscience.org/library/papers/22461093 | PubMed |
| 5 | 22966306 | Chemosensitivity of lung cancer: Differences between the primary lesion and lymph node metastasis. | Oncol Lett | 2010 | https://conductscience.org/library/papers/22966306 | PubMed |
| 6 | 11911296 | Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. | Anticancer Res | 2001 | https://conductscience.org/library/papers/11911296 | PubMed |
| 7 | 25954633 | A comprehensive review on clinical applications of comet assay. | J Clin Diagn Res | 2015 | https://conductscience.org/library/papers/25954633 | PubMed |
| 8 | 25267064 | Direct chemosensitivity monitoring ex vivo on undissociated melanoma tumor tissue by impedance spectroscopy. | Cancer Res | 2014 | https://conductscience.org/library/papers/25267064 | PubMed |
| 9 | 24008432 | Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. | Nat Rev Drug Discov | 2013 | https://conductscience.org/library/papers/24008432 | PubMed |
| 10 | 12168915 | Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. | Anticancer Res | 2002 | https://conductscience.org/library/papers/12168915 | PubMed |
| 11 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 12 | 25665006 | A Big Bang model of human colorectal tumor growth. | Nat Genet | 2015 | https://conductscience.org/library/papers/25665006 | PubMed |
| 13 | 31866766 | Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. | Cancer Cell Int | 2019 | https://conductscience.org/library/papers/31866766 | PubMed |
| 14 | 31862441 | Developments in zebrafish avatars as radiotherapy sensitivity reporters - towards personalized medicine. | EBioMedicine | 2020 | https://conductscience.org/library/papers/31862441 | PubMed |
| 15 | 18955806 | Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay. | J Korean Med Sci | 2008 | https://conductscience.org/library/papers/18955806 | PubMed |
| 16 | 27832950 | The chick embryo chorioallantoic membrane (CAM) assay. | Reprod Toxicol | 2017 | https://conductscience.org/library/papers/27832950 | PubMed |
| 17 | 28945830 | Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28945830 | PubMed |
| 18 | 23332421 | Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. | Clin Colorectal Cancer | 2013 | https://conductscience.org/library/papers/23332421 | PubMed |
| 19 | 9291821 | The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. | Eur J Cancer | 1997 | https://conductscience.org/library/papers/9291821 | PubMed |
| 20 | 26536825 | Precision medicine for cancer with next-generation functional diagnostics. | Nat Rev Cancer | 2015 | https://conductscience.org/library/papers/26536825 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42926325 | Live-cell FRET imaging-based efficacy prediction of EGFR-TKIs in EGFR L858R-mutant NSCLC. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42926325 | PubMed |
| 42212169 | Re-evaluating breast malignant pleural effusion: toward evidence-based, precision-aligned care with organoids. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42212169 | PubMed |
| 42040583 | The patient journey and guideline-concordant care in colorectal cancer-is current practice enough? | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42040583 | PubMed |
| 41828436 | Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828436 | PubMed |
| 41228245 | Functional Assays to Guide Personalized Oncological Treatment of Patients with Soft-Tissue Sarcomas. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228245 | PubMed |
| 41144783 | Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane. | Int J Cancer | 2026 | https://conductscience.org/library/papers/41144783 | PubMed |
| 40113943 | Lab-in-a-Fiber detection and capture of cells. | Sci Rep | 2025 | https://conductscience.org/library/papers/40113943 | PubMed |
| 39337925 | Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine. | Life (Basel) | 2024 | https://conductscience.org/library/papers/39337925 | PubMed |
| 39100682 | Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms. | Front Immunol | 2024 | https://conductscience.org/library/papers/39100682 | PubMed |
| 38252369 | Adhesion, metastasis, and inhibition of cancer cells: a comprehensive review. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/38252369 | PubMed |
| 38132201 | Immunofluorescence-Based Assay for High-Throughput Analysis of Multidrug Resistance Markers in Non-Small Cell Lung Carcinoma Patient-Derived Cells. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/38132201 | PubMed |
| 37235664 | Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer. | Sci Adv | 2023 | https://conductscience.org/library/papers/37235664 | PubMed |
| 35879922 | Functional Drug Screening in the Era of Precision Medicine. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/35879922 | PubMed |
| 35406568 | Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35406568 | PubMed |
| 35328603 | Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35328603 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| COL11A2 | 1302 | PubTator's text mining | https://conductscience.org/library/genes/1302 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34646385
GET https://conductscience.org/api/papers/v1/34646385/references?page=2